Project Grant SB1AI191674
Award Date 8/1/26
Completion Date 7/31/28
Dollars Obligated $1M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded Sciogen LLC $314,363 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop novel therapeutics targeting respiratory syncytial virus (RSV) infection through G-receptor binding inhibition. The Phase I Small Business Innovation Research award funds evaluation of a new class of RSV inhibitors identified through high-throughput screening. Work includes assessment of biological...
- The National Institute of Allergy and Infectious Diseases, part of the Department of Health and Human Services, awarded $853,847 to Massachusetts General Hospital on August 21, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds characterization of virologic and immunologic features of RSV immunoprophylaxis and escape. The recipient will sequence the genomes of approximately 3,000 biobanked and prospectively collected respiratory syncytial virus...
- The National Institute of Allergy and Infectious Diseases awarded Mapp Biopharmaceutical, Inc., $1.986 million in project grant funding on September 24, 2025, to develop MBP002, a fully human monoclonal antibody product for respiratory syncytial virus (RSV) immunoprophylaxis in neonates and infants. The award operates under the Allergy and Infectious Diseases Research program (CFDA 93.855). MBP002 is formulated as a two-antibody cocktail administered in a single dose per RSV season, designed...
- The National Institute of Allergy and Infectious Diseases awarded University of Kansas Medical Center Research Institute, Inc. $193,750 on July 7, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct exploratory research on the role of cell-surface glycoRNAs in respiratory syncytial virus infection. The research will define the sequences and secondary structures of glycoRNAs that scaffold nucleolin, an RNA-binding protein and critical RSV entry receptor, on...
- The National Institute of Allergy and Infectious Diseases awarded the Scripps Research Institute $1.62 million on July 20, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop and characterize novel inhibitors targeting the polymerase and endonuclease activities of the L protein of human pathogenic mammarenaviruses. The recipient will conduct biochemical, cell-based functional, structural, and viral genetics studies to define the mechanisms of action of two...
- The National Institute of Allergy and Infectious Diseases awarded Fred Hutchinson Cancer Center $191,376 on August 11, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to map escape mutations in respiratory syncytial virus fusion protein and monitor for antibody-resistant viral strains. The recipient will develop a deep mutational scanning platform to comprehensively measure the effects of all possible mutations on cell entry and neutralization by clinically...
- The National Institute of Allergy and Infectious Diseases awarded Yale University $130,923 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop data-science approaches for evaluating and forecasting respiratory syncytial virus transmission. The research addresses knowledge gaps in how host factors—age, contact patterns, and within-host viral load kinetics—shape individual infectiousness and RSV disease transmission. The work comprises three...
- The National Institute of Allergy and Infectious Diseases awarded University of Wisconsin - Madison $449,375 on August 3, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to elucidate the structural mechanisms of respiratory syncytial virus and human metapneumovirus assembly. The project applies cryo-electron tomography, cryo-correlative light and electron microscopy, and cryo-focused ion beam milling, complemented by molecular biology and biochemical approaches, to...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Massachusetts General Hospital $364,484 through the Allergy and Infectious Diseases Research program (CFDA 93.855) on July 25, 2025, to support research on soluble guanylate cyclase (SGC) pathway activation as a novel bronchodilation strategy for respiratory syncytial virus (RSV) bronchiolitis in pediatric populations. The research project, with an ultimate completion date of June 30, 2027,...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Vanderbilt University Medical Center a $3.3 million Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) on August 11, 2025, to examine the real-world effectiveness and uptake of newly approved Respiratory Syncytial Virus (RSV) maternal vaccines and monoclonal antibodies. The research will assess comparative effectiveness, cost-effectiveness, safety, and...